DYAI

Over the past six months, Dyadic announced a collaboration with Intralink to expand its presence in Japan and South Korea. The company rebranded to Dyadic Applied BioSolutions. Dyadic and Proliant Health & Biologicals commercially launched AlbuFree™ DX. Dyadic and Fermbox Bio launched Animal-Origin-Free Recombinant DNase I. Dyadic Applied BioSolutions and Inzymes ApS announced planned commercialization of a non-animal dairy enzyme. Dyadic partnered with IBT Bioservices for distribution of recombinant protein products. The company reported its 2025 financial results on March 25, 2026, with lower revenue and a wider net loss, but projected product revenue growth for 2026. As of May 4, 2026, the stock price was $0.75 per share, a decline of 36.36% from May 5, 2025.